In approximately 90% of cases, this metabolic reprogramming in ccRCC is often related to von Hippel-Lindau (VHL) tumor-suppressor mutations; in VHL-deficient ccRCC, HIF1α increases the expression of GLUT-1, which then promotes cellular glucose uptake [4]. Here, SLC2A1 is linked to neoplasm.